Sibutramin

Sibutramin – the synthetic medicine applied at treatment of alimentary obesity.

Pharmacological action

Sibutramin with the active component of the same name treats the drugs accelerating approach of feeling of saturation. It leads to decrease in consumption of food without psychological tension, and as result, to weight reduction.

Medicines with the maintenance of a sibutramin do not release monoamines and do not belong to MAO inhibitors. Also medicine has no affinity to adrenergic, serotonergic, muskarinovy, dopaminergic, benzodiazepine, histamine and NMDA to receptors.

Sibutramin's analogs

Sibutramin's analogs on active agent are drugs Goldlayn, Meridia, Lindaksa and Slimiya.

If necessary the doctor can replace a medicine with one of Sibutramin's analogs with similar therapeutic action. Treat them Reduksin containing in quality of active components сибутрамин both cellulose microcrystallic and Phepranonum with active agent Amphepramonum.

Indications to Sibutramin's use

The medicine Sibutramin according to the instruction is appointed as a part of a complex maintenance therapy of excess body weight:

• At alimentary obesity (a body weight index – from 30 kg/sq.m and more);
• At alimentary obesity (a body weight index – from 27 kg/sq.m and more) if there are other risk factors connected with excess body weight including a lipidemia and a diabetes mellitus of the second type.

Contraindications

It is contraindicated to apply Sibutramin to weight loss:

• At serious violations of food, for example, at nervous bulimia or nervous anorexia;
• At the organic reason of obesity;
• Against the background of Turett's syndrome;
• Against the background of mental diseases;
• At occlusal diseases of peripheral arteries;
• Against the background of coronary heart disease, inborn heart diseases, chronic heart failure in a decompensation stage;
• At uncontrollable arterial hypertension;
• Against the background of arrhythmia, tachycardia and various disturbances of cerebral circulation, including tranzitorny;
• Against the background of heavy abnormal liver functions and kidneys;
• At a hyperthyroidism;
• Against the background of a pheochromocytoma;
• At a benign hyperplasia of a prostate with formation of a residual urine;
• During pregnancy and in the period of a lactation;
• At the established pharmacological, drug or alcohol addiction;
• Against the background of glaucoma;
• At hypersensitivity to the active agent of the same name or other components which are a part of medicine.

Sibutramin according to the instruction it is contraindicated to apply along with some medicines, namely:

• With MAO inhibitors;
• With antidepressants, neuroleptics, tryptophane or other medicines which have the oppressing effect on the central nervous system;
• With any other medicines which action is directed to decrease in body weight.

Extra care is demanded by Sibutramin's appointment for weight loss:

• Against the background of a hypopotassemia and a hypomagnesiemia;
• Along with the medicines promoting increase in an interval of QT;
• Against the background of the abnormal liver functions and kidneys proceeding in easy and moderate severity;
• At epilepsy;
• Along with drugs which can cause increase in arterial pressure and heart rate, including a number of drugs for cold, cough and allergy.

Due to the lack of necessary researches, Sibutramin according to the instruction is not appointed to people 65 years are more senior.

Route of administration of Sibutramin

Sibutramin, as a rule, appoint in an initial dose 10 mg a day. If weight reduction happens too slowly (less than 2 kg in a month), in the absence of the expressed side effects, connected with drug intake, the daily dosage is increased to 15 mg. If rates of weight reduction do not increase at the specified dosage, cancel Sibutramin's use.

As a rule, medicine is applied not less than a year. If within the first three months of therapy it is not possible to reach the sufficient level of decrease in body weight (not less than 5% of initial level), Sibutramin's use is cancelled. Also the medicine is cancelled if during therapy a set of body weight is observed.

Sibutramin appoint only when any other undertaken measures do not lead to weight reduction (less than 5 kg in three months).

Treatment needs to be carried out in a complex. It has to include change of a nutritious diet and increase in physical activity. Change of the usual way of life which caused obesity is a necessary condition for preservation of the achieved result on weight reduction using Sibutramin.

During therapy it is necessary to control the arterial pressure and change of heart rate. Also during survey it is necessary to pay the attention to pains in a thorax, the arising hypostases progressing диспноэ.

It is not recommended to take alcohol during Sibutramin's use.

Side effects of Sibutramin for weight loss

From frustration of the alimentary system most often at Sibutramin's use according to reviews there is an appetite loss, dryness in a mouth, the lock and nausea, can develop tranzitorny increase in activity of liver enzymes slightly less often.

Also against the background of Sibutramin's reception according to reviews there can be frustration of other systems which are expressed as:

• Sweating strengthening, sleeplessness, headaches, concern, dizziness, paresthesias, convulsive attacks and change of taste (central and peripheral nervous system);
• Shenleyn-Genokh's purpura and thrombocytopenia (coagulant system of blood);
• Heart consciousness, tachycardia, slight increase of arterial pressure, erubescence with a caumesthesia, an exacerbation of hemorrhoids (cardiovascular system).

In some cases Sibutramin's use according to reviews can cause acute intersticial nephrite, more expressed increase in arterial pressure and a mezangiokapillyarny glomerulonephritis.

In most cases emergence of side effects at Sibutramin's use for weight loss is observed in the first month of therapy, and their frequency and expressiveness decrease over time.

Medicinal interaction

During treatment it is necessary to consider that at simultaneous use of Sibutramin with ketokonazoly, erythromycin, troleandomitsiny, the cyclosporine and other medicines inhibiting activity of an isoenzyme of CYP3A4 concentration can increase in plasma of metabolites of Sibutramin that promotes insignificant increase in an interval of QT.

The risk of development of a serotoninovy syndrome increases at simultaneous use of Sibutramin with:

• Agonists of 5-HT1-receptors;
• Selective serotonin reuptake inhibitors, for example, with fluoxetine, tsitalopramy, sertraline and paroksetiny;
• Opioid analgetics;
• Derivatives of alkaloids of an ergot;
• Antibechic drugs of the central action.

Storage conditions

Sibutramin treats medicines of a prescription issue with standard storage conditions.